

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10526285
	Filing Date		2005-03-02
	First Named Inventor	Dharmadhikari, et al.	
	Art Unit	1614	
	Examiner Name	Krass, Frederick	
	Attorney Docket Number	006420.00004	

U.S.PATENTS								
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.								
U.S.PATENT APPLICATION PUBLICATIONS								
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1	20050063913	A1	2005-03-24	Pruitt et al.			
If you wish to add additional U.S. Published Application citation information please click the Add button.								
FOREIGN PATENT DOCUMENTS								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button								
NON-PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						T ⁵

/Chris Simmons/

06/21/2008

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10526285
Filing Date	2005-03-02
First Named Inventor	Dharmadhikari, et al.
Art Unit	1614
Examiner Name	Krass, Frederick
Attorney Docket Number	006420.00004

1	VENNING, et al. Absorption Distrib. Drugs, Symp., 1964, pages 150-156, Volume Dated 1963, G. D. Searle Co. Ltd., London.	<input type="checkbox"/>
2	OVERDIEK, et al. Clinical Pharmacology & Therapeutics, Nov 1986, Volume 40, issue 5, pages 531-536.	<input type="checkbox"/>
3	BERGSTROM, et al. Bioavailability and Bioequivalence: General Concepts and Overview, pages 1-43, Retrieved from the internet: <URL:http://medicine.iupui.edu/clinical/F813_spring2006/Q_ClinicalPKF813Lecture16A07March2006BioavailabilityandBioequivalencerevised.pdf>	<input type="checkbox"/>
4	GIBALDI, et al. Pharmacokinetics (2nd edition, revised and expanded), 1982, pages 37-38, Marcel Dekker, New York.	<input type="checkbox"/>
5	WONG, et al. Fast-dissolving microparticles fail to show improved oral bioavailability, Journal of Pharmacy and Pharmacology, 2006, Volume 58, pages 1319-1326.	<input type="checkbox"/>
6	KAHELA, et al. The Effect of Ball Milling with Microcrystalline Cellulose on the Bioavailability of Spironolactone in Dogs, Acta Pharmaceutica Fennica, 1978, Volume 87, pages 185-188.	<input type="checkbox"/>
7	KRAML, et al. Bioavailability Studies with Etolodac in Dogs and Man, Biopharmaceutics & Drug Disposition, 1984, Volume 5, pages 63-74.	<input type="checkbox"/>
8	Letter and Enclosure from Lawrence Goldkind at the Food and Drug Administration to Linda B. Fischer at Elan Pharmaceuticals, dated 8/30/02, 8 pages.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Chris Simmons/	Date Considered	06/21/2008
--------------------	-----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.